Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the Company, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the Company, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG (Medigene or the Company, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the Company, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program...
Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the Company, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will...
Medigene to Present Favorable Safety Profile of TCR-T Cells
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology